Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial

Recruiting now · Not applicable

Conditions studied: Lung Cancer, Relapse/Recurrence

In brief

For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early relapse. To address this clinical challenge, many studies have focused on understanding the clinicopathologic characteristics associated with an increased risk of early relapse. Despite these efforts, we can identify patients at risk but cannot pinpoint which individuals will actually experience early relapse. Studies on adjuvant therapy have shown improved survival in cases of more advanced disease but have not demonstrated a reduction in early relapse rates. In our preliminary analysis of previous study data, we observed that patients with a smaller reduction in circulating tumor cells (CTCs) within the first three days after surgery, followed by an increase on the third-day post-operation, are more likely to experience early relapse during regular monitoring. This pattern may be indicative of minimal residual disease. By combining trends in circulating tumor cell variations with pathologic characteristics, we aim to select patients for adjuvant therapy who are at high risk of developing early relapse. The objective of our study is to employ screening based on circulating tumor cell dynamics and pathologic features to identify patients likely to experience early relapse and to assess the effectiveness of adjuvant therapy in these cases.

Key facts

Study ID

NCT06262386

Run by

Chang Gung Memorial Hospital

People needed

358

Starts

2023-08-01

Expected to finish

2028-07-31

Last updated by the study team

2024-02-16

Who can join

Age: 20 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who presented with resectable disease ( Clinical stage 1a to 3a)
• Patients who received tumor resection

You may not qualify if…

• Pathologic stage greater than stage 3b or 4
• Pathologic stage less than stage 1a1
• Could not complete treatment course
• Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance

Where it is running

• Ching-Yang Wu — Taoyuan City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.